| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7714006 | KING PHARMS | Methods of modifying the bioavailability of metaxalone |
Dec, 2021
(2 years ago) | |
| US7122566 | KING PHARMS | Metaxalone products, method of manufacture, and method of use |
Feb, 2026
(1 year, 9 months from now) | |
Skelaxin is owned by King Pharms.
Skelaxin contains Metaxalone.
Skelaxin has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Skelaxin are:
- US7714006
Skelaxin is available in tablet;oral dosage forms.
Skelaxin can be used as treatment of musculoskeletal conditions, use of metaxalone for treatment of musculoskeletal conditions.
The generics of Skelaxin are possible to be released after 06 February, 2026.
Drugs and Companies using METAXALONE ingredient
Treatment: Use of metaxalone for treatment of musculoskeletal conditions; Treatment of musculoskeletal conditions
Dosage: TABLET;ORAL
How can I launch a generic of SKELAXIN before it's drug patent expiration?
More Information on Dosage
SKELAXIN family patents
